Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.

By D. Hershman, L. Kushi, T. Shao, D. Buono, A. Kershenbaum, W. Tsai, L. Fehrenbacher, S. Gomez, Sunita Q Miles, A. Neugut. Journal of Clinical Oncology, 2010

792 citations recorded by the source corpus.

Subfields: Family Practice, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/224d73e6fcef779320fd50963977716137319966

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Runowicz
2. Mandi L Pratt-Chapman
3. R. Cowens-Alvarado
4. E. Warner
5. S. Edge
6. Rachel S. Cannady
7. G. Lyman
8. L. Marks

Citations in the corpus

• American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline (2016, positive): “The rest generally tolerate tamoxifen.(139) Poor compliance/adherence to therapy has been shown to result in an increased risk of breast cancer recurrence, so helping patients manage their symptoms and encouraging drug compliance is important.”